Company
Dialybrid
Milan medtech built on a decade of biohybrid materials research. Develops arteriovenous grafts for dialysis vascular access.
1 story
Regulatory News has published 1 story about Dialybrid on 22 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 22 September 2026.
This page is generated from Regulatory News’ editorial coverage of Dialybrid. It is not an advertisement.
On the record
- Company
- Dialybrid
- Headquarters
- Milan, Italy
- Founded
- Building on roughly a decade of biohybrid materials research before Dialybrid's commercial spin-out
- Regulator
- EU clinical-trial framework (pilot study registration number not independently confirmed at publication)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
